体外膜氧合治疗COVID-19相关重度ARDS的回顾性队列研究
这项在巴黎索邦大学医院网络五家ICU开展的回顾性队列研究,纳入83例接受ECMO的COVID-19相关重度ARDS患者,估计60天时45%患者存活且已出ICU,31%死亡,42%发生大出血;作者认为ECMO救治后的60天生存率与既往重度ARDS的ECMO研究相似。
要点
- ECMO前94%患者已行俯卧位通气,中位驱动压18 cm H2O,PaO2/FiO2为60 mm Hg。
- ECMO启动后60天,估计45%患者存活且已出ICU,31%死亡。
- 42%患者发生大出血,5%发生出血性卒中,需关注出血风险。
核心结论
- ECMO救治的COVID-19相关重度ARDS患者估计60天生存率与近2年发表的重度ARDS ECMO研究相似。
- 若再次出现COVID-19疫情,对优化治疗后仍存在难治性呼吸衰竭的患者应考虑ECMO。
研究设计与样本
- 回顾性队列研究,在巴黎索邦大学医院网络五家ICU开展,纳入接受ECMO的COVID-19相关ARDS患者。
- 共83例患者完成60天随访,中位年龄49岁(IQR 41-56),61例(73%)为男性。
- 采用多状态Cox模型估计ECMO启动后90天内各状态占用概率及状态间转换概率。
主要发现
- ECMO前78例(94%)患者接受过俯卧位通气,中位驱动压18 cm H2O(IQR 16-21),PaO2/FiO2为60 mm Hg(IQR 54-68)。
- ECMO启动后60天,各状态估计概率为:仍在ECMO 6%(95%CI 3-14)、在ICU且已脱离ECMO 18%(95%CI 11-28)、存活且已出ICU 45%(95%CI 35-56)、死亡31%(95%CI 22-42)。
- 35例(42%)患者发生大出血,4例(5%)发生出血性卒中,30例死亡。
临床怎么用
- 对COVID-19相关重度ARDS经优化治疗(包括俯卧位通气)仍难治性呼吸衰竭者,可考虑ECMO。
- ECMO期间应警惕大出血和出血性卒中,本队列大出血发生率为42%。
局限性
- 为单网络回顾性队列研究,样本量有限(83例完成60天随访)。
- 随访截至2020年7月10日,结果可能受当时诊疗策略影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with COVID-19 who develop severe acute respiratory distress syndrome (ARDS) can have symptoms that rapidly evolve to profound hypoxaemia and death. The efficacy of extracorporeal membrane oxygenation (ECMO) for patients with severe ARDS in the context of COVID-19 is unclear. We aimed to establish the clinical characteristics and outcomes of patients with respiratory failure and COVID-19 treated with ECMO. METHODS: This retrospective cohort study was done in the Paris-Sorbonne University Hospital Network, comprising five intensive care units (ICUs) and included patients who received ECMO for COVID-19 associated ARDS. Patient demographics and daily pre-ECMO and on-ECMO data and outcomes were collected. Possible outcomes over time were categorised into four different states (states 1-4): on ECMO, in the ICU and weaned off ECMO, alive and out of ICU, or death. Daily probabilities of occupation in each state and of transitions between these states until day 90 post-ECMO onset were estimated with use of a multi-state Cox model stratified for each possible transition. Follow-up was right-censored on July 10, 2020. FINDINGS: From March 8 to May 2, 2020, 492 patients with COVID-19 were treated in our ICUs. Complete day-60 follow-up was available for 83 patients (median age 49 [IQR 41-56] years and 61 [73%] men) who received ECMO. Pre-ECMO, 78 (94%) patients had been prone-positioned; their median driving pressure was 18 (IQR 16-21) cm H2O and PaO2/FiO2 was 60 (54-68) mm Hg. At 60 days post-ECMO initiation, the estimated probabilities of occupation in each state were 6% (95% CI 3-14) for state 1, 18% (11-28) for state 2, 45% (35-56) for state 3, and 31% (22-42) for state 4. 35 (42%) patients had major bleeding and four (5%) had a haemorrhagic stroke. 30 patients died. INTERPRETATION: The estimated 60-day survival of ECMO-rescued patients with COVID-19 was similar to that of studies published in the past 2 years on ECMO for severe ARDS. If another COVID-19 outbreak occurs, ECMO should be considered for patients developing refractory respiratory failure despite optimised care. FUNDING: None.
引用
- Schmidt M, Hajage D, Lebreton G, et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study. Lancet Respir Med. 2020. PMID: 32798468. doi:10.1016/S2213-2600(20)30328-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。